JP6755186B2 - ω−３組成物、剤形および使用法 - Google Patents

ω−３組成物、剤形および使用法 Download PDF

Info

Publication number
JP6755186B2
JP6755186B2 JP2016569985A JP2016569985A JP6755186B2 JP 6755186 B2 JP6755186 B2 JP 6755186B2 JP 2016569985 A JP2016569985 A JP 2016569985A JP 2016569985 A JP2016569985 A JP 2016569985A JP 6755186 B2 JP6755186 B2 JP 6755186B2
Authority
JP
Japan
Prior art keywords
fatty acids
dosage form
study
item
dha
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016569985A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017516811A5 (enExample
JP2017516811A (ja
Inventor
オーラブ サンドネス，
オーラブ サンドネス，
ブルース エー． ミラー，
ブルース エー． ミラー，
ヨルン ダイアベルク，
ヨルン ダイアベルク，
スティーン シュテンダー，
スティーン シュテンダー，
Original Assignee
マリン イングリーディエンツ， エルエルシー
マリン イングリーディエンツ， エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by マリン イングリーディエンツ， エルエルシー, マリン イングリーディエンツ， エルエルシー filed Critical マリン イングリーディエンツ， エルエルシー
Publication of JP2017516811A publication Critical patent/JP2017516811A/ja
Publication of JP2017516811A5 publication Critical patent/JP2017516811A5/ja
Application granted granted Critical
Publication of JP6755186B2 publication Critical patent/JP6755186B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/60—Fish, e.g. seahorses; Fish eggs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/618—Molluscs, e.g. fresh-water molluscs, oysters, clams, squids, octopus, cuttlefish, snails or slugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
JP2016569985A 2014-06-06 2015-06-05 ω−３組成物、剤形および使用法 Active JP6755186B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462009145P 2014-06-06 2014-06-06
US62/009,145 2014-06-06
US201462019289P 2014-06-30 2014-06-30
US62/019,289 2014-06-30
PCT/US2015/034372 WO2015188046A1 (en) 2014-06-06 2015-06-05 Omega-3 compositions, dosage forms, and methods of use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020068334A Division JP2020105224A (ja) 2014-06-06 2020-04-06 ω−３組成物、剤形および使用法

Publications (3)

Publication Number Publication Date
JP2017516811A JP2017516811A (ja) 2017-06-22
JP2017516811A5 JP2017516811A5 (enExample) 2018-07-19
JP6755186B2 true JP6755186B2 (ja) 2020-09-16

Family

ID=54767418

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016569985A Active JP6755186B2 (ja) 2014-06-06 2015-06-05 ω−３組成物、剤形および使用法
JP2020068334A Pending JP2020105224A (ja) 2014-06-06 2020-04-06 ω−３組成物、剤形および使用法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2020068334A Pending JP2020105224A (ja) 2014-06-06 2020-04-06 ω−３組成物、剤形および使用法

Country Status (14)

Country Link
US (4) US9675575B2 (enExample)
EP (2) EP3151826A4 (enExample)
JP (2) JP6755186B2 (enExample)
KR (1) KR102400958B1 (enExample)
CN (1) CN106687113B (enExample)
AU (1) AU2015269307C1 (enExample)
BR (1) BR112016028561A8 (enExample)
CA (1) CA2950344C (enExample)
CL (1) CL2016003131A1 (enExample)
MX (1) MX2016015791A (enExample)
MY (1) MY186566A (enExample)
RU (1) RU2741965C2 (enExample)
TW (1) TWI725937B (enExample)
WO (1) WO2015188046A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10709680B2 (en) * 2011-07-18 2020-07-14 Physicians Recommended Nutriceuticals, Llc Methods for treating dry eye
TWI725937B (zh) * 2014-06-06 2021-05-01 美商海洋原料公司 ω-３組成物、劑型及使用方法
CN110958731A (zh) 2018-09-21 2020-04-03 鸿盛国际有限公司 发光二极管并联电路
FR3103355B1 (fr) 2019-11-26 2024-05-31 Polaris Composition d’huile de micro-organismes enrichie en acides gras polyinsaturés
FR3151183A1 (fr) 2023-07-20 2025-01-24 Microphyt Nouvelle utilisation d’un extrait de la microalgue Phaeodactylum tricornutum

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8819110D0 (en) 1988-08-11 1988-09-14 Norsk Hydro As Antihypertensive drug & method for production
FR2731015B1 (fr) 1995-02-24 1997-05-30 Sci Sartone Procede d'enrichissement enzymatique d'huiles d'origine marine et les triglycerides d'acides gras polyinsatures ainsi obtenus
DE69612011T3 (de) * 1995-11-24 2010-02-18 Unilever N.V. Zusammensetzung auf basis von fischöl
US7799365B2 (en) * 2001-04-06 2010-09-21 Burnbrae Farms Limited Liquid egg composition including fish oil with omega-3 fatty acid
US7169385B2 (en) * 2003-09-29 2007-01-30 Ronald G. Udell Solubilized CoQ-10 and carnitine
SE0303513D0 (sv) * 2003-12-19 2003-12-19 Pronova Biocare As Use of a fatty acid composition comprising at least one of epa and dha or any combinations thereof
US20070020340A1 (en) * 2005-07-25 2007-01-25 David Rubin Fish oil products for reducing cholesterol, low density lipoprotein, and hypertension
EP1968402A2 (en) 2005-10-07 2008-09-17 Ocean Nutrition Canada Limited Salts of fatty acids and methods of making and using thereof
EP1968567B1 (en) 2005-12-20 2014-06-18 Cenestra, Llc Omega 3 fatty acid formulations
US9265745B2 (en) 2005-12-21 2016-02-23 Brudy Technology S.L. Use of DHA, EPA or DHA-derived EPA for treating a pathology associated with cellular oxidative damage
EP2031985A2 (en) 2006-06-23 2009-03-11 The Procter and Gamble Company Concentrated omega-3 fatty acids and mixtures containing them
US8410181B2 (en) 2006-09-19 2013-04-02 The Trustees Of Columbia University In The City Of New York Omega-3 diglyceride emulsions
CA2685272A1 (en) * 2007-04-26 2008-11-06 Patrick Adlercreutz A polyunsaturated fatty acid (pufa) enriched marine oil comprising eicosapentaenoic acid (epa) and docosahexaenoic acid (dha), and a process of production thereof
US20100119600A1 (en) 2007-06-01 2010-05-13 Joar Opheim Substances for reducing occurrence of major cardiac events comprising red yeast rice extract and omega-3 polyunsaturated fatty acid or derivative thereof
CL2008002020A1 (es) 2007-07-12 2008-11-14 Ocean Nutrition Canada Ltd Metodo de modificacion de un aceite, que comprende hidrolizar gliceridos con una solucion de lipasa thermomyces lanuginosus, separar la fraccion de acido graso saturado de la fraccion de glicerido hidrolizado y esterificar los gliceridos hidrolizados en la presencia de candida antarctica lipasa b; y composicion de aceite.
KR101502191B1 (ko) * 2007-07-30 2015-03-12 닛폰 스이산 가부시키가이샤 Ｅｐａ 농축유 및 ｄｈａ 농축유의 제조 방법
KR101045397B1 (ko) 2008-07-04 2011-06-30 주식회사동우산업 오메가-3 지방산 함량이 높은 정제 오징어유의 제조방법
GB0813599D0 (en) 2008-07-24 2008-09-03 Pharma Marine As Method
US8592439B2 (en) * 2008-08-07 2013-11-26 Spa Societa Prodotti Antibiotici S.P.A. Long-term treatment of symptomatic heart failure
US20100236137A1 (en) * 2008-09-23 2010-09-23 LiveFuels, Inc. Systems and methods for producing eicosapentaenoic acid and docosahexaenoic acid from algae
CN102421422A (zh) * 2009-03-09 2012-04-18 普罗诺瓦生物医药挪威公司 含有脂肪酸油混合物和表面活性剂的组合物及其方法和用途
CN101695487B (zh) * 2009-09-22 2012-01-18 北京百慧生化制药有限责任公司 一种高纯度epa-e、dha-e的多烯酸乙酯乳剂
FR2955459B1 (fr) 2010-01-28 2013-11-22 Polaris Composition huileuse riche en monoglycerides de dha
US20110223246A1 (en) * 2010-03-10 2011-09-15 Joar Opheim Docosahexaenoic acid bound in phospholipids and method of recovering same from a natural source
EP2560633B8 (en) 2010-04-23 2020-08-12 The Government of the United States, as represented by The Secretary of the Army Intravenous omega-3 fatty acid compositions & method of use
WO2012038833A1 (en) * 2010-09-24 2012-03-29 Pronova Biopharma Norge As Process for concentrating omega-3 fatty acids
US20120252888A1 (en) * 2011-03-29 2012-10-04 Palupa Medical Ltd. Compositions and Methods for Treating Neurologic Disorders
AU2012347606A1 (en) * 2011-12-08 2014-06-26 Metaproteomics, Llc Supplemented oil compositions and methods for improved health
TW201343203A (zh) * 2011-12-22 2013-11-01 普諾華生物製藥諾治股份有限公司 含有ω－３脂肪酸之經明膠／藻酸鹽延緩釋放型膠囊，其製法及用途
AU2013259503B2 (en) 2012-05-10 2017-03-16 Solutex Na Llc Oils with anti-inflammatory activity containing natural specialized proresolving mediators and their precursors
WO2014057362A2 (en) 2012-09-24 2014-04-17 Aker Biopharma As Omega -3 compositions
US20130310457A1 (en) 2013-07-25 2013-11-21 Niral Ramesh Solid-in-oil dispersions
TWI725937B (zh) 2014-06-06 2021-05-01 美商海洋原料公司 ω-３組成物、劑型及使用方法

Also Published As

Publication number Publication date
EP3151826A1 (en) 2017-04-12
KR102400958B1 (ko) 2022-05-20
US20160243068A1 (en) 2016-08-25
TW201613571A (en) 2016-04-16
TWI725937B (zh) 2021-05-01
CA2950344A1 (en) 2015-12-10
CN106687113A (zh) 2017-05-17
BR112016028561A2 (pt) 2017-08-22
MY186566A (en) 2021-07-27
BR112016028561A8 (pt) 2021-06-29
JP2020105224A (ja) 2020-07-09
CA2950344C (en) 2023-09-19
US20210308086A1 (en) 2021-10-07
WO2015188046A1 (en) 2015-12-10
US11160777B2 (en) 2021-11-02
AU2015269307C1 (en) 2019-10-03
RU2016149416A3 (enExample) 2018-12-05
US20170252313A1 (en) 2017-09-07
RU2741965C2 (ru) 2021-02-01
JP2017516811A (ja) 2017-06-22
EP3151826A4 (en) 2018-01-24
US10034849B2 (en) 2018-07-31
US10172819B2 (en) 2019-01-08
US20180303784A1 (en) 2018-10-25
CL2016003131A1 (es) 2017-06-09
MX2016015791A (es) 2017-05-30
RU2016149416A (ru) 2018-07-10
EP3906920A1 (en) 2021-11-10
KR20170018825A (ko) 2017-02-20
AU2015269307A1 (en) 2017-01-05
US9675575B2 (en) 2017-06-13
AU2015269307B2 (en) 2019-03-14
CN106687113B (zh) 2021-09-03

Similar Documents

Publication Publication Date Title
JP2020105224A (ja) ω−３組成物、剤形および使用法
JP2008525392A (ja) Ｅｐａによる重度のメランコリー型うつ病の治療
EP1968567A1 (en) Omega 3 fatty acid formulations
LU87570A1 (fr) Composition d'acides gras
JP6664328B2 (ja) エイコサペンタエン酸アルキルエステルを含有する組成物及びその製造方法
JP2014512351A (ja) 神経障害の治療用組成物
JP2020182497A (ja) 一価不飽和脂肪酸組成物およびアテローム性動脈硬化症を処置するための使用
JP2021155756A (ja) 水産物由来遊離１価不飽和脂肪酸又はその低級アルコールエステルの製造方法
JPH0761954B2 (ja) コレステロール低下または上昇抑制剤
JP4707839B2 (ja) 糖尿病予防治療剤
JP4904751B2 (ja) 生体内ｄｈａ合成促進剤
JP6787891B2 (ja) コミュニケーションスキルの改善のためのリン脂質調製物
JP4786030B2 (ja) ナチュラルキラー細胞活性化剤
JP2001288079A (ja) 特異的殺癌細胞剤及びこれを配合してなる組成物
JP2001278786A (ja) 高尿酸性疾患予防治療剤
AU2006331645B2 (en) Omega 3 fatty acid formulations
JPH07216382A (ja) トコフェロール強化精製エゴマ油、それを含有する脂肪輸液剤及び経口投与製剤

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180605

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180605

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20190206

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190215

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190514

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190815

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20191205

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200406

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20200406

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20200526

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200608

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200721

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20200728

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20200825

R150 Certificate of patent or registration of utility model

Ref document number: 6755186

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250